Federal contract award
75A50119C00061
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN73 — SPECIALIZED MEDICAL SERVICES - ADVANCED DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $26.4M |
| Current contract value | $26.4M |
| Potential contract value / ceiling | $33.7M |
| Start date | Sep 26, 2019 |
| Current end date | Dec 31, 2027 |
| Potential end date | Dec 31, 2027 |
| Latest award activity | Sep 4, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 4, 2025 | P00005 | $2.3M | SUPPLEMENTAL FUNDING FOR $3,711,014.00 TO CLIN 002, DE-OB $1,434,722.76 IN CANCELING FUNDS UNDER OS241378, ADD ALTERNATE COR, AND OTHER ADMIN REQUIREMENTS. |
| May 1, 2024 | P00004 | $0 | NO COST MODIFICATION TO REVISE THE POP WITHIN PRISM TO MATCH BILATERAL MODIFICATION DATES. |
| Mar 16, 2023 | P00003 | $0 | NO COST MODIFICATION TO REVISE THE POP FOR CLIN 0006 OPTION 4 |
| Jul 20, 2022 | P00002 | $475.0K | AMGEN INC - SUPPLEMENTAL FUNDING FOR CLIN 0001, BASE AWARD. |
| Jan 31, 2022 | P00001 | $2.2M | EXERCISE OPTION 4 CLIN 0006 DEVICE FEASIBILITY (SELF ADMINISTRATION KIT), REVISE THE CONTRACTING OFFICER, ADDITIONAL FAR CLAUSES INCLUDED IN FULL TEXT WAS REVISED TO ADD HHSAR 352.232-71 ELECTRONIC SUBMISSION OF PAYMENT REQUESTS ELECTRONIC SUBMISSION |
| Sep 26, 2019 | 0 | $21.5M | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO |
Estimated positioning window
Dec 31, 2026 – Jun 30, 2027
60/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 60/100. Available recorded signals: 55 points.
- Contract end 2027-12-31 (425 days from calculation)
- +25 points
- 2 historical awards in this buyer and category group
- +10 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2025-09-04
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.